The red-hot market has plenty of room for additional therapies from big-name players and clinical-stage companies alike.

Rezdiffra (resmetirom) is a brand-name oral tablet prescribed for nonalcoholic steatohepatitis (NASH) in certain situations. It is typically taken once per day. The dosage varies based on a person’s ...

In its first full quarter on the market, Madrigal Pharmaceuticals’ Rezdiffra, the first treatment for metabolic dysfunction-associated steatohepatitis (MASH), achieved sales of $14.6 million. The ...

Rezdiffra (resmetirom) is a brand-name drug prescribed for a type of liver disease called metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH) ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The cost of Rezdiffra may vary depending on your insurance coverage, your treatment plan, and the pharmacy you choose. Rezdiffra may need to be purchased through a specialty pharmacy authorized to ...

Rezdiffra (resmetirom) is a brand-name prescription oral tablet used to treat a certain type of liver disease. It is not a weight-loss medication. Rezdiffra was approved by the Food and Drug ...

Madrigal Pharmaceuticals’ fatty liver disease drug Rezdiffra generated $137 million in sales during the first quarter of 2025, well above analysts’ consensus expectation of $112 million.

Add Yahoo as a preferred source to see more of our stories on Google. The FDA approved Rezdiffra to treat non-cirrhotic non-alcoholic steatohepatitis (NASH). Photo courtesy of U.S. Food and Drug ...

(RTTNews) - Madrigal Pharmaceuticals, Inc. (MDGL) announced that the U.S. Food and Drug Administration (FDA) has approved Rezdiffra (resmetirom) along with diet and exercise for the treatment of ...

Millions of Americans whose livers develop scar tissue due to a common disease now have the first approved drug, Rezdiffra, to treat the condition, the U.S. Food and Drug Administration announced ...